| Accession Number: | 0001209191-23-018001 |
| Date: | 2023-03-08 |
| Issuer: | TARSUS PHARMACEUTICALS, INC. (TARS) |
| Original Submission Date: |
NEERVANNAN SESHADRI
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY) | 15.0 | 2023-03-08 | deemed execution date | A | 48,116 (a) | 2033-03-08 | common stock 48,116 | $15.00 | 48,116 | direct | ||
| RESTRICTED STOCK UNITS | 0.0 | 2023-03-08 | deemed execution date | A | 32,592 (a) | common stock 32,592 | $0.00 | 32,592 | direct |
| ID | footnote |
|---|---|
| f1 | 25% of the option shares shall vest on march 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the reporting person's continuous service. |
| f2 | each restricted stock unit ("rsu") represents a contingent right to receive one share of the company's common stock. |
| f3 | 25% of the rsus will vest on march 15th of each of 2024, 2025, 2026, and 2027, subject to the reporting person's continuous service. |
